Early diagnostics and therapeutics for Alzheimer’s disease – how early can we get there?
- 1 September 2006
- journal article
- review article
- Published by Informa UK Limited in Expert Review of Neurotherapeutics
- Vol. 6 (9), 1293-1306
- https://doi.org/10.1586/14737175.6.9.1293
Abstract
Alzheimer’s disease (AD) is a major threat for the rapidly aging world population. AD is the leading cause of dementia and a major cause of death in developed countries. The disease puts a tremendous practical, emotional and financial burden on individuals and governments. Clinicians and researchers in the AD field face great challenges: the pathophysiological processes that cause AD are not well understood, definite diagnosis of AD requires autopsy, and therapeutic options are limited to treating the symptoms rather than the cause of the disease. Nevertheless, new insights into the earliest events that lead to development of AD increase hope that reliable diagnostics and efficacious therapies may emerge.Keywords
This publication has 122 references indexed in Scilit:
- Cyclohexanehexol inhibitors of Aβ aggregation prevent and reverse Alzheimer phenotype in a mouse modelNature Medicine, 2006
- TMP21 is a presenilin complex component that modulates γ-secretase but not ɛ-secretase activityNature, 2006
- En route to early diagnosis of Alzheimer's disease – are we there yet?Trends in Biotechnology, 2005
- CSF biomarkers for mild cognitive impairment and early Alzheimer's diseaseClinical Neurology and Neurosurgery, 2005
- Curcumin Inhibits Formation of Amyloid β Oligomers and Fibrils, Binds Plaques, and Reduces Amyloid in VivoPublished by Elsevier BV ,2005
- Self-Propagating, Molecular-Level Polymorphism in Alzheimer's ß-Amyloid FibrilsScience, 2005
- Memantine Treatment in Patients With Moderate to Severe Alzheimer Disease Already Receiving DonepezilJAMA, 2004
- Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of PathogenesisScience, 2003
- Protofibrils, the unifying toxic molecule of neurodegenerative disorders?Nature Neuroscience, 2001
- The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formationNature Neuroscience, 2001